Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 205.63

+1.0%

11:29 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Spekulatius who wrote (28655)	4/5/1999 4:57:00 PM
From: Cacaito	Read Replies (1) of 32384

Ligand will fund more of the Seragen pipeline one way or another, meaning their own money, or alliances with big pharma, or even a stock the ALRI way (Allergan/Ligand special company to develop many of the retinoid and rexinoid compounds, if I remember well both Panretin and Targretin were financed this way, not sure). Seragen fusion platform work will continue in other disorders, no reference right now, but in a recent post there was a reference to a different Ontak line of work. Money spend in research by a company it is still good for tax considerations, so your earnings are tax at a lower rate for years to come. One of the value of adquiring almost defunct companies is their tax significant carryover losses. Correction: Aronex drug for CTCL is Atragen, a form of All-trans-retinoic acid similar to the Panretin/Targretin way of work, but less receptor specific. Atragen has more side effects and more toxicity. Not Nyotran which is for fungal infections.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next